Geode Capital Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Geode Capital Management’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,050,879	Closed	-$268K	–	4861
2023 Q1	$268K	Buy	1,050,879 +1,934	+0.2%	+$1.75K	﹤0.01%	3910
2022 Q4	$1.24M	Buy	1,048,945 +13,513	+1%	+$28.4K	﹤0.01%	3256
2022 Q3	$2.11M	Buy	1,035,432 +688,154	+198%	+$1.17M	﹤0.01%	3066
2022 Q2	$534K	Buy	347,278 +62,715	+22%	+$245K	﹤0.01%	3725
2022 Q1	$1.44M	Buy	284,563 +226,510	+390%	+$1.03M	﹤0.01%	3431
2021 Q4	$359K	Buy	+58,053	New	+$518K	﹤0.01%	4212

Geode Capital Management's PEAR Position: Q2 2023 in Review

Geode Capital Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 1,050,879 shares — an estimated $268K sold.

Geode Capital Management first reported a position in PEAR in Q4 2021 and held it in 6 quarters. The position peaked at $2.11M in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Geode Capital Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Geode Capital Management sold 1,050,879 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $268K.
Geode Capital Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 6 quarters.
Geode Capital Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $2.11M in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.